Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 4/20 | 0.31 |
| ▸ | CA1 | P00915 | 4/20 | 0.31 |
| ▸ | CA2 | P00918 | 4/20 | 0.31 |
| ▸ | CA9 | Q16790 | 4/20 | 0.31 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 3/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7027273 | 0.86 | CA12 (0.38) | ADORA2BALDH1A1LMNAHPGDCA12 | |
| SCHEMBL7025769 | 0.85 | KDM4E (0.43) | ALDH1A1LMNAKDM4E | |
| SCHEMBL7031980 | 0.82 | COMT (0.35) | ALDH1A1LMNAHPGDCA12CA1 | |
| SCHEMBL7033130 | 0.82 | ADORA2B (0.31) | ADORA2BALDH1A1LMNAHPGDCA12 | |
| SCHEMBL7471650 | 0.82 | ADORA2B (0.31) | ADORA2BALDH1A1LMNAHPGDCA12 | |
| SCHEMBL7027998 | 0.81 | ADORA2B (0.32) | ADORA2B | |
| SCHEMBL7034524 | 0.81 | MAPT (0.42) | LMNAMAPK8MAPK10KDM4E | |
| SCHEMBL7030429 | 0.80 | ALDH1A1 (0.38) | ALDH1A1LMNAHPGDCA12CA1 | |
| SCHEMBL7032445 | 0.80 | CA12 (0.36) | ALDH1A1LMNAHPGDCA12CA1 | |
| SCHEMBL7031174 | 0.80 | COMT (0.36) | ALDH1A1LMNAHPGDCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1232505-C | Substituted sulfonamido (thio) carbonyl compounds | BAYER AG (DE) | 2005-12-21 | — | — | CN | disclosed |
| CN-1439631-A | Substituted sulfonamido (thio) carbonyl compounds | BAYER AG (DE) | 2003-09-03 | — | — | CN | disclosed |
| US-20030162979-A1 | Substituted sulphonylamino(thio)carbonyl compounds | MULLER KLAUS-HELMUT (DE) | 2003-08-28 | — | — | US | disclosed |
| CN-1105717-C | Substituted sulfonamido (thio) carbonyl compounds | BAYER AG (DE) | 2003-04-16 | — | — | CN | disclosed |
| US-6441195-B1 | 2-ALKOXYCARBONYL-3-SULPHONAMIDE, SULPHONYL ISOCYANATE OR SULPHONYL ISOTHIOCYANATE-THIOPHENES; PRE- OR POSTEMERGENCE HERBICIDES; EFFICIENCY | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-27 | — | — | US | disclosed |
| US-6180567-B1 | REACTING 2-ALKOXYCARBONYL-BENZENESULFONAMIDE DERIVATIVE WITH 1,2,4-(1H)TRIAZOLE-5-(THI)ONE DERIVATIVE | BAYER AKTIENGESELLSCHAFT (DE) | 2001-01-30 | — | — | US | disclosed |
| CN-1207099-A | Substituted sulfonamido (thio) carbonyl compounds | BAYER AG (DE) | 1999-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162979-A1 | Substituted sulphonylamino(thio)carbonyl compounds | CBR3, CTH, CBR1 | ADORA2B 2669/4885ALDH1A1 261/4885LMNA 4111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.